Bristol Myers Interest Coverage Over Time

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets. Continue to Bristol Myers Performance and Bristol Myers Correlation.

Search Competitors Fundamentals Over Time Against Interest Coverage

 
Refresh
Bristol Myers Interest Coverage is fairly stable at the moment as compared to the past year. Bristol Myers reported Interest Coverage of 9.01 in 2019. Net Income to Non Controlling Interests is likely to grow to about 21.6 M in 2020, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop slightly above 5.8 B in 2020.

Specify up to 10 symbols:


Cross Equities Interest Coverage Analysis

Compare Bristol Myers Squibb and related stocks such as GW Pharmaceuticals Plc, Novartis AG, Grifols S A, Eli Lilly And, Gilead Sciences, Johnson Johnson, Merck Inc, Astrazeneca PLC, GlaxoSmithKline PLC Interest Coverage Over Time
Select Fundamental

20102011201220132014201520162017201820192020
49.841351.419475.288514710938.601145.104639.083233.072216.611217.048
81.403327.297111.111114.741237.05132.257318.291512.63337.61374.30854.4203
32.466732.466757.667657.667657.667657.667657.667633.524633.524630.1733.9789
3.7513.945519.114111.091212.167418.088814.73717.704619.34518.744816.1288
84.057112129.736815.557812.763510.271727.724618.428627.96729.01379.2493
25.771328.565720.26879.51795.410111.30228.42276.41715.44534.59754.7197
5.697311.846710.54469.95655.284616.11773.48655.6788136147158

Bristol Myers Squibb and related stocks such as GW Pharmaceuticals Plc, Novartis AG, Grifols S A, Eli Lilly And, Gilead Sciences, Johnson Johnson, Merck Inc, Astrazeneca PLC, GlaxoSmithKline PLC Interest Coverage description

My Equities

My Current Equities and Potential Positions

BMY - USA Stock
Bristol Myers Squibb
<div class='circular--portrait-small' style='font-weight: 700;background:#689CFD;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>BM</div>
Bristol Myers Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
RegionNorth America
ExchangeBATS Exchange
$60.19
Continue to Bristol Myers Performance and Bristol Myers Correlation. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page